$12.27
4.07%
Nasdaq, Sep 12, 10:00 pm CET

Tandem Diabetes Care, Inc. Stock price

$12.27
+1.17 10.49% 1M
-6.50 34.63% 6M
-23.75 65.94% YTD
-31.49 71.96% 1Y
-45.48 78.75% 3Y
-95.13 88.58% 5Y
-111.83 90.11% 10Y
-180.33 93.63% 20Y
Nasdaq, Closing price Fri, Sep 12 2025
-0.52 4.07%

Key metrics

Basic
Market capitalization
$829.1m
Enterprise Value
$822.9m
Net debt
positive
Cash
$315.4m
Shares outstanding
67.5m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
0.8 | 0.8
EV/Sales
0.8 | 0.8
EV/FCF
negative
P/B
6.2
Financial Health
Equity Ratio
27.2%
Return on Equity
-36.5%
ROCE
-14.9%
ROIC
-24.0%
Debt/Equity
2.3
Financials (TTM | estimate)
Revenue
$1.0b | $1.0b
EBITDA
$-75.9m | $32.5m
EBIT
$-93.0m | $-140.5m
Net Income
$-205.5m | $-144.0m
Free Cash Flow
$-54.2m
Growth (TTM | estimate)
Revenue
25.9% | 8.3%
EBITDA
38.2% | 139.4%
EBIT
33.1% | -41.7%
Net Income
-50.5% | -50.0%
Free Cash Flow
15.8%
Margin (TTM | estimate)
Gross
52.6%
EBITDA
-7.6% | 3.2%
EBIT
-9.3%
Net
-20.5% | -14.2%
Free Cash Flow
-5.4%
More
EPS
$-3.1
FCF per Share
$-0.8
Short interest
13.6%
Employees
3k
Rev per Employee
$350.0k
Show more

Is Tandem Diabetes Care, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,008 stocks worldwide.

Tandem Diabetes Care, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

30 Analysts have issued a Tandem Diabetes Care, Inc. forecast:

13x Buy
43%
16x Hold
53%
1x Sell
3%

Analyst Opinions

30 Analysts have issued a Tandem Diabetes Care, Inc. forecast:

Buy
43%
Hold
53%
Sell
3%

Financial data from Tandem Diabetes Care, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
1,002 1,002
26% 26%
100%
- Direct Costs 475 475
17% 17%
47%
526 526
35% 35%
53%
- Selling and Administrative Expenses 420 420
20% 20%
42%
- Research and Development Expense 199 199
11% 11%
20%
-76 -76
38% 38%
-8%
- Depreciation and Amortization 17 17
6% 6%
2%
EBIT (Operating Income) EBIT -93 -93
33% 33%
-9%
Net Profit -205 -205
50% 50%
-21%

In millions USD.

Don't miss a Thing! We will send you all news about Tandem Diabetes Care, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Tandem Diabetes Care, Inc. Stock News

Neutral
GlobeNewsWire
2 days ago
NEW YORK, Sept. 12, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Tandem Diabetes Care, Inc. (NASDAQ: TNDM) resulting from allegations that Tandem Diabetes Care may have issued materially misleading business information to the investing public.
Neutral
Seeking Alpha
5 days ago
Tandem Diabetes Care, Inc. (NASDAQ:TNDM ) Morgan Stanley 23rd Annual Global Healthcare Conference September 10, 2025 9:15 AM EDT Company Participants John Sheridan - President, CEO & Director Leigh Vosseller - Executive VP, CFO & Treasurer Presentation Unknown Analyst All right. Good morning, everyone.
Neutral
Business Wire
11 days ago
SAN DIEGO--(BUSINESS WIRE)---- $TNDM #diabetes--Tandem t:slim Mobile App authorized by Health Canada for iPhone and Android Phones. The app will be available for Canadian customers later this year.
More Tandem Diabetes Care, Inc. News

Company Profile

Tandem Diabetes Care, Inc. engages in the design, development, and commercialization of products for people with insulin-dependent diabetes. Its flagship product, t:slim X2 Insulin Delivery System, operates as a small insulin pump. The company was founded by Paul M. DiPerna on January 27, 2006 and is headquartered in San Diego, CA.

Head office United States
CEO John Sheridan
Employees 2,650
Founded 2006
Website www.tandemdiabetes.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today